Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.Methods This double-blind, placebo-controlled trial was undertaken in 974 hospitals in 42 countries. 18,695 patients with previously manifest or increased risk of vascular disease were randomly assigned to receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314). Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke, as determined via central adjudication. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00263042.Findings At a mean follow-up of 13.8 months (95% CI 13.6-14.0), the trial was prematurely discontinued because of concerns by health regulatory authorities in three countries about suicide in individuals receiving rimonabant. All randomised participants were analysed. At the close of the trial (Nov 6, 2008), the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 364 (3.9%) patients assigned to rimonabant and 375 (4.0%) assigned to placebo (hazard ratio 0.97, 95% CI 0.84-1.12, p=0.68). With rimonabant, gastrointestinal (3038 [33%] vs 2084 [22%]), neuropsychiatric (3028 [32%] vs 1989 [21%]), and serious psychiatric side-effects (232 [2.5%] vs 120 [1.3%]) were significantly increased compared with placebo. Four patients in the rimonabant group and one in the placebo group committed suicide.Interpretation The premature termination of this trial has important lessons for drug development. A drug that was being marketed for weight loss, but being tested for improving cardiovascular outcomes, induced a level of serious neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the drug and the trial were abruptly terminated.Funding Sanofi-Aventis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [6]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [6]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009) · Health Affairs · doi:10.1377/hlthaff.28.5.w822 · Cited by 2,957
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Polyunsaturated fatty acids and their metabolites in brain function and disease
Bazinet, R. P., & Layé, S. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3820 · Cited by 1,605
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationTargeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 660
Metadata
- Authors
- Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., & Bhatt, D. L.
- Affiliations
- Hôpital Lariboisière (FR)
- University of Edinburgh (GB)
- Brigham and Women's Hospital (US)
- Brown University (US)
- Kerckhoff Klinik (DE)
- Pitié-Salpêtrière Hospital (FR)
- University of Rochester (US)
- Sunnybrook Health Science Centre (CA)
- Sanofi (France) (FR)
- VA Boston Healthcare System (US)
- Corresponding author
- Topol, Eric J
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 376
- Issue
- 9740
- Pages
- 517-523
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2112222692
- Cited by
- 266
- References
- 15
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 15 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 14 · 2018: 10 · 2017: 21 · 2016: 21 · 2015: 16 · 2014: 17 · 2013: 15 · 2012: 26
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Sanofi
- Cleveland Clinic
- Institute of Clinical and Translational Sciences
- National Center for Research Resources (UL1RR025774)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- rimonabant, cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, cardiovascular risk, obesity, neuropsychiatric adverse effects, suicide risk, gastrointestinal adverse effects, drug safety, trial termination, anti-obesity drugs, drug development, cardiovascular disease prevention, primary prevention of cardiovascular disease, secondary prevention of cardiovascular disease
- MeSH terms
- Rimonabant, Aged, Aged, 80 and over, Mental Disorders, Cardiovascular Diseases, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Obesity, Piperidines, Pyrazoles, Suicide, Drug Approval, Cannabinoid Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60935-x
- The paper
- Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., & Bhatt, D. L. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(10)60935-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.